Graphite Bio reports dosing the first patient with its lead CRISPR therapy candidate nula-cel in Phase 1/2 trial for sickle cell disease.

Last week, Editas Medicine announced successful engraftment of the first patient dosed with the CRISPR-based therapeutic candidate EDIT-301 for the...

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

Sickle cell disease (SCD) is associated with lowered blood and oxygen flow, which leads to a range of symptoms and life-limiting complications....

This week's clinical update includes news from Allogene Therapeutics and Graphite Bio. The U.S. Food and Drug Administration (FDA) recently granted...

This clinical update looks at Graphite Bio's sickle cell disease candidate GPH101. GPH101 is an ex vivo CRISPR-edited cell therapy that is anticipated...

In 2022, we celebrate a decade of CRISPR as a game-changing tool in research and medicine. The last 10 years have been phenomenal, and CRISPR cures...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...